Table S1.

Efficacy of lines of therapy 1-10.

Lines of therapy	1	%	2	%	3	%	4	%	5	%	6	%	7	%	8	%	9	%	10	%
n patients	303		241		190		153		123		96		67		46		31		23
Response rates
CR	55	18	26	11	5	3	8	5	2	2	2	2	0	0	2	4	0	0	0	0
VGPR	77	25	40	17	29	15	20	13	11	9	8	8	8	12	3	7	1	3	3	13
PR	104	34	74	31	71	37	39	25	26	21	18	19	16	24	9	20	8	26	4	17
MR	24	8	31	13	14	7	19	12	18	15	15	16	7	10	5	11	2	6	3	13
SD	31	10	44	18	48	25	39	25	38	31	32	33	16	24	19	41	11	35	6	26
PD	3	1	9	4	7	4	11	7	12	10	8	8	12	18	3	7	3	10	2	9
NA	9	3	17	7	16	8	16	10	16	13	13	14	8	12	5	11	6	19	5	22
PR or better	236	78	140	58	105	55	67	44	39	32	28	29	24	36	14	30	9	29	7	30
MR or better	260	86	171	71	119	63	86	56	57	46	43	45	31	46	19	41	11	35	10	43
Progression-free survival
Median	18		10		8		6		4		3		3		2		3		4
3 months or longer	208	69	155	64	122	64	94	61	55	45	34	35	29	43	13	28	12	39	10	43
6 months or longer	169	56	116	48	88	46	59	39	27	22	18	19	17	25	8	17	7	23	4	17
1 year or longer	127	42	73	30	38	20	23	15	13	11	11	11	5	7	3	7	2	6	0	0
Time to next treatment
Median	8		6		6		6		3		3		4		3		4		5
3 months or longer	171	56	127	53	109	57	89	58	49	40	29	30	26	39	14	30	14	45	10	43
6 months or longer	135	45	97	40	78	41	56	37	28	23	9	9	14	21	8	17	10	32	6	26
1 year or longer	99	33	57	24	31	16	17	11	13	11	3	3	4	6	4	9	4	13	0	0

CR = complete response or stringent complete response; VGPR = very good partial response; PR = partial response; MR = minimal response; SD = stable disease; PD = progressive disease; NA = not measured or unmeasurable.